3 year term is because of the nature of prostate cancer

DNDN failed "time to progress" primary end point of its trial design, and is claiming survival end point, while survival is the best and ultimate goal or end point, it takes a long time to actually measure this end point, because you have to wait for patient to die or pass a time frame, in DNDN's current survival analysis, I think they are using 3 years as cut off point.

I agree with you that game is far from over, I will gradually rebuild my position as I found money, it is still a good drug and patients need it. I have heard stories over internet that some patients from outside US wants to come here to take part in trial, because that is their only hope so far.